文献速递甲状腺疾病

甲状腺激素停药后的临床结局:更新系统综述与荟萃分析

Clinical Outcomes after Deprescribing Thyroid Hormone Therapy: An Updated Systematic Review and Meta-Analysis.
PubMed 文献 · Thyroid · 2026-11-02

停药后约37%患者保持甲状腺功能正常,亚临床甲减(SCH)患者(41%)高于初始明显甲减患者(11%);60%患者需重新启动治疗,明显甲减者升至87%。甲状腺自身抗体阳性、超声异质性和较高基线TSH与重启治疗相关。

要点

  • 停药后约37%患者维持甲功正常,SCH者成功率高于明显甲减者。
  • 总体60%患者需重启治疗,初始明显甲减者达87%。
  • 抗体阳性、超声异质性和高基线TSH与重启治疗相关。

核心结论

  • 约37%患者停用甲状腺激素后保持甲功正常,初始因SCH治疗者成功率更高。
  • 结果支持对特定患者考虑停药,尤其初始治疗指征不明确者,需结构化方案密切监测。

研究设计与样本

  • 系统综述与荟萃分析,检索截至2026年9月25日,纳入RCT和观察性研究。

主要发现

  • 甲状腺自身抗体阳性、甲状腺超声异质性表现和较高基线TSH水平与重启治疗相关。
  • 停药后甲状腺相关症状总体无变化,不良事件不常见。

临床怎么用

  • 对初始治疗指征不明确者(如部分SCH)可考虑在结构化方案下停药。
  • 停药期间需密切生化监测,并预设重启治疗的标准。

局限性

  • 异质性高(I2达94.5%和97.1%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Levothyroxine (LT4) is widely prescribed, often for subclinical hypothyroidism (SCH), despite limited evidence of clinical benefit in patients without overt hypothyroidism. This updated systematic review synthesizes current evidence on biochemical, symptom, and safety outcomes following thyroid hormone (TH) discontinuation. METHODS: In this systematic review, electronic databases were searched from inception to September 25, 2026, for randomized controlled trials (RCTs) and observational studies evaluating supervised TH discontinuation. Primary outcomes included postdiscontinuation thyroid function, symptom changes, adverse events, and need for therapy reinitiation. Random-effects meta-analyses estimated pooled proportions and mean differences. RESULTS: Twenty-three studies met inclusion criteria (22 observational studies, 1 RCT), most evaluating LT4 monotherapy discontinuation (n = 20). Twenty-one studies including 2020 participants reported categorical TH status outcomes; 37% of participants (CI, 26%-48%; I2 = 94.5%) remained euthyroid after discontinuation. Euthyroidism was less frequent among patients with initial overt hypothyroidism (11%, CI, 2%-38%) than among those with SCH (41%, CI, 21%-65%). Eleven studies (1104 participants) reported TH reinitiation, with 60% of patients restarting therapy (CI, 39%-78%; I2 = 97.1%) in the overall population, increasing to 87% (CI, 66%-96%) among those with overt hypothyroidism. Thyroid autoantibody positivity, heterogeneous thyroid ultrasound findings, and higher baseline TSH levels were associated with therapy reinitiation. Thyroid-related symptoms after discontinuation were generally unchanged, and adverse events were uncommon. CONCLUSIONS: Approximately 37% of patients remained euthyroid after TH discontinuation, with higher success rates among those initially treated for SCH. These findings support consideration of deprescribing in selected patients, particularly those without clear indications for treatment initiation, using a structured approach with close biochemical monitoring and predefined criteria for therapy reinitiation.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Toloza FJK, Ho K, Burgos N, et al. Clinical Outcomes after Deprescribing Thyroid Hormone Therapy: An Updated Systematic Review and Meta-Analysis. Thyroid. 2026. PMID: 42969098. doi:10.1177/10507256261502928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。